Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up

KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study

zacks.com - 25/Jun 15:17

Krystal Biotech rises 4% after dosing begins in a phase III study of KB803 eye drops to treat rare DEB-related corneal damage.

Nektar Therapeutics Is Up 150%: What’s Happening With NKTR Stock?

wn.com - 24/Jun 18:29

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b REZOLVE-AD study of...

Nektar Therapeutics Is Up 150%: What’s Happening With NKTR Stock?

wn.com - 24/Jun 18:29

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b REZOLVE-AD study of...

AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease (AB Science SA)

wn.com - 23/Jun 07:57

) PRESS RELEASE NEW PEER-REVIEWED DATA PROVIDE STRONG EVIDENCE SUPPORTING MASITINIB'S POTENTIAL FOR THE TREATMENT OF ALZHEIMER'S DISEASE THROUGH A...

AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease (AB Science SA)

wn.com - 23/Jun 07:57

) PRESS RELEASE NEW PEER-REVIEWED DATA PROVIDE STRONG EVIDENCE SUPPORTING MASITINIB'S POTENTIAL FOR THE TREATMENT OF ALZHEIMER'S DISEASE THROUGH A...

Triglyceride-Glucose Index May Predict Faster Cognitive Decline in Early Phases of Alzheimer Disease

drugs.com - 15:06

MONDAY, June 30, 2025 -- For patients with mild cognitive impairment (MCI) associated with Alzheimer disease (AD), those in the highest tertile of the...

VKTX Initiates Phase 3 Study on Obesity Candidate VK2735

zacks.com - 26/Jun 15:12

Viking begins phase III VANQUISH program for VK2735, targeting weight loss in obese adults with or without type II diabetes.

VKTX Initiates Phase 3 Study on Obesity Candidate VK2735

zacks.com - 26/Jun 15:12

Viking begins phase III VANQUISH program for VK2735, targeting weight loss in obese adults with or without type II diabetes.

NVO Reports New Positive Phase III Data on Mim8 in Hemophilia A

zacks.com - 23/Jun 15:25

Novo Nordisk's Mim8 shows strong safety and patient preference in the phase IIIb hemophilia A study switching from Hemlibra to Mim8.

NVO Reports New Positive Phase III Data on Mim8 in Hemophilia A

zacks.com - 23/Jun 15:25

Novo Nordisk's Mim8 shows strong safety and patient preference in the phase IIIb hemophilia A study switching from Hemlibra to Mim8.

Rubriques :

Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up

Articles similaires

KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study

Nektar Therapeutics Is Up 150%: What’s Happening With NKTR Stock?

Nektar Therapeutics Is Up 150%: What’s Happening With NKTR Stock?

AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease (AB Science SA)

AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease (AB Science SA)

Triglyceride-Glucose Index May Predict Faster Cognitive Decline in Early Phases of Alzheimer Disease

VKTX Initiates Phase 3 Study on Obesity Candidate VK2735

VKTX Initiates Phase 3 Study on Obesity Candidate VK2735

NVO Reports New Positive Phase III Data on Mim8 in Hemophilia A

NVO Reports New Positive Phase III Data on Mim8 in Hemophilia A

Les derniers communiqués